RWJ-67657featured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:510234
CAS#:215303-72-3
Description:RWJ-67657 is a potent p38 MAPK inhibitor, which inhibited the release of TNF-alpha by lipopolysaccharide (a monocyte stimulus)-treated human peripheral blood mononuclear cells with an IC(50) of 3 nM, as well as the release of TNF-alpha from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (a T cell stimulus), with an IC(50) value of 13 nM. This compound was approximately 10-fold more potent than the literature standard p38 kinase inhibitor SB 203580 in all p38 dependent in vitro systems tested.
Price and Availability
This agent is in stock
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 510234Name: RWJ-67657CAS#: 215303-72-3Chemical Formula: C27H24FN3OExact Mass: 425.19034Molecular Weight: 425.49736Elemental Analysis: C, 76.21; H, 5.69; F, 4.46; N, 9.88; O, 3.76
Synonym:RWJ67657; RWJ-67657; RWJ 67657
IUPAC/Chemical Name:4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol
InChi Key:QSUSKMBNZQHHPA-UHFFFAOYSA-N
InChi Code:InChI=1S/C27H24FN3O/c28-24-13-11-22(12-14-24)26-27(23-15-17-29-18-16-23)31(25(30-26)10-4-5-20-32)19-6-9-21-7-2-1-3-8-21/h1-3,7-8,11-18,32H,5-6,9,19-20H2
SMILES Code:OCCC#CC1=NC(C2=CC=C(F)C=C2)=C(C3=CC=NC=C3)N1CCCC4=CC=CC=C4
Technical Data
Additional Information
References
1: Westra J, Kułdo JM, van Rijswijk MH, Molema G,Limburg PC. Chemokine production and E-selectin expression in activatedendothelial cells are inhibited by p38 MAPK (mitogen activated proteinkinase) inhibitor RWJ 67657. Int Immunopharmacol. 2005Jul;5(7-8):1259-69. Epub 2005 Apr 26. PubMed PMID: 15914330.
2: Westra J, Limburg PC, de Boer P, van Rijswijk MH. Effects of RWJ67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on theproduction of inflammatory mediators by rheumatoid synovial fibroblasts.Ann Rheum Dis. 2004 Nov;63(11):1453-9. PubMed PMID: 15479895; PubMedCentral PMCID: PMC1754789.
3: Westra J, Doornbos-van der Meer B, de Boer P, van Leeuwen MA, vanRijswijk MH, Limburg PC. Strong inhibition of TNF-alpha production andinhibition of IL-8 and COX-2 mRNA expression in monocyte-derivedmacrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK)inhibitor. Arthritis Res Ther. 2004;6(4):R384-92. Epub 2004 Jun 21.PubMed PMID: 15225374; PubMed Central PMCID: PMC464924.
4: Parasrampuria DA, de Boer P, Desai-Krieger D, Chow AT, Jones CR.Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, aspecific p38 mitogen-activated protein kinase inhibitor: afirst-in-human study. J Clin Pharmacol. 2003 Apr;43(4):406-13. PubMedPMID: 12723461.
5: Faas MM, Moes H, Fijen JW, Muller Kobold AC, Tulleken JE, ZijlstraJG. Monocyte intracellular cytokine production during human endotoxaemiawith or without a second in vitro LPS challenge: effect of RWJ-67657, ap38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol.2002 Feb;127(2):337-43. PubMed PMID: 11876759; PubMed Central PMCID:PMC1906333.
6: Fijen JW, Zijlstra JG, De Boer P, Spanjersberg R, Tervaert JW, VanDer Werf TS, Ligtenberg JJ, Tulleken JE. Suppression of the clinical andcytokine response to endotoxin by RWJ-67657, a p38 mitogen-activatedprotein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol.2001 Apr;124(1):16-20. PubMed PMID: 11359438; PubMed Central PMCID:PMC1906020.
7: Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA,Wu W, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Wachter MP,Siekierka JJ. RWJ 67657, a potent, orally active inhibitor of p38mitogen-activated protein kinase. J Pharmacol Exp Ther. 1999Nov;291(2):680-7. PubMed PMID: 10525088.
